第一条 为了进一步完善公司法人治理结构，保证苏州赛分科技股份有限公司 （以下简称"公司"）所有股东充分行使权利，根据中国证监会《上市公司治理准 则》、《上海证券交易所科创板股票上市规则》、《苏州赛分科技股份有限公司章 程》（以下简称"《公司章程》"）及其他有关规定，制定本实施细则。 第二条 本实施细则所指的累积投票制，是指股东会在选举两名以上（含两名） 董事时采用的一种投票方式。即公司选举董事时，每位股东所持有的每一股份都拥 有与应选董事总人数相等的投票权，股东既可以用所有的投票权集中选举一人，也 可以分散选举数人，最后按得票多少依次决定董事人选。 第三条 本实施细则所称"董事"包括独立董事和非独立董事。 第四条 股东会选举产生的董事人数及结构应符合公司章程的规定。 苏州赛分科技股份有限公司 累积投票制实施细则 第五条 股东会对董事候选人进行表决前，会议主持人应明确告知与会股东对候 选董事实行累积投票方式，股东会工作人员应该置备适合实行累积投票方式的选票。 董事会秘书应对累积投票方式、选票填写方法做出说明和解释。 第六条 运用累积投票制选举公司董事的具体表决办法如下： （一）累积投票制的票数计算法 1. 每位 ...

第一条 为规范苏州赛分科技股份有限公司（以下简称"公司"）股东会的表 决机制，保护投资者合法权益，根据《中华人民共和国公司法》（以下简称" 《公司法》"）、《上市公司股东会规则（2025年修订）》、《上海证券交易 所科创板股票上市规则》、《上海证券交易所科创板上市公司自律监管指引第 1号——规范运作》等相关法律、行政法规、规章、规范性文件和《苏州赛分 科技股份有限公司章程》（以下简称"《公司章程》"）的规定，特制订本细则。 第二条 本细则所称公司股东会网络投票系统（以下简称"网络投票系统"） 是指上海证券交易所（以下简称"上交所"）利用网络与通信技术，为公司股东 非现场行使股东会表决权提供服务的信息技术系统。上交所网络投票系统包括 下列投票平台： （一）交易系统投票平台； （二）互联网投票平台（网址：vote.sseinfo.com）。 第三条 公司召开股东会，应当按照相关规定向股东提供网络投票方式，履 行股东会相关的通知和公告义务，做好股东会网络投票的相关组织和准备工作。 第四条 公司为股东提供网络投票方式的，应当按照上交所相关临时公告格 式指引的要求，使用上交所公告编制软件编制股东会相关公告，并按规定披露 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥83,587,089.19, representing an increase of 8.87% compared to ¥76,776,735.66 in the same period last year[3]. - The net profit attributable to shareholders decreased by 1.02% to ¥23,712,621.06 from ¥23,957,060.85 year-on-year[3]. - The net profit for Q1 2025 is CNY 23,880,736.67, a decrease of 2.55% compared to CNY 24,507,260.57 in Q1 2024[15]. - The company reported a comprehensive income total of CNY 23,828,821.34 for Q1 2025, compared to CNY 24,697,375.86 in Q1 2024, indicating a decrease of about 3.5%[17]. - Basic earnings per share for Q1 2025 is CNY 0.0593, down from CNY 0.0654 in Q1 2024, representing a decline of approximately 9.3%[17]. Cash Flow and Liquidity - The net cash flow from operating activities dropped significantly by 97.56% to ¥396,039.16, down from ¥16,229,892.37 in the previous year[3]. - The cash flow from operating activities shows a net increase of CNY 396,039.16, significantly lower than CNY 16,229,892.37 in the same period last year[18]. - The company generated CNY 21,547,815.06 in net cash flow from investing activities in Q1 2025, a significant improvement compared to a negative cash flow of CNY 23,686,987.66 in Q1 2024[19]. - The financing activities generated a net cash flow of CNY 175,038,543.72 in Q1 2025, compared to a negative cash flow of CNY 2,044,558.45 in Q1 2024, indicating a strong improvement in financing[19]. - Cash and cash equivalents increased to ¥299,817,279.15 from ¥103,080,898.09, representing a growth of 189.5%[10]. Assets and Liabilities - The total assets at the end of the reporting period increased by 14.94% to ¥1,358,984,272.87 from ¥1,182,310,293.37 at the end of the previous year[3]. - Current assets as of March 31, 2025, totaled ¥785,539,359.11, a significant increase of 33.0% from ¥590,390,238.19 at the end of 2024[10]. - Total assets reached ¥1,358,984,272.87, an increase of 15.0% from ¥1,182,310,293.37 at the end of 2024[12]. - Total liabilities decreased to ¥70,716,025.89 from ¥84,269,862.24, a reduction of 16.1%[12]. - Shareholders' equity increased to ¥1,288,268,246.98, up 17.3% from ¥1,098,040,431.13 at the end of 2024[12]. Operating Costs and Expenses - Total operating costs for Q1 2025 were ¥53,628,737.30, up 14.7% from ¥46,742,557.97 in Q1 2024[14]. - Operating costs included ¥21,613,466.86 in operating expenses, which rose 20.5% from ¥18,010,478.67 in Q1 2024[14]. - The total tax expenses for Q1 2025 are CNY 3,984,561.36, an increase from CNY 3,010,143.26 in Q1 2024, representing a rise of approximately 32.3%[15]. Research and Development - Research and development expenses totaled ¥11,284,285.02, which is an increase of 10.23% compared to ¥10,237,437.10 in the same period last year[3]. - R&D expenses accounted for 13.50% of operating revenue, up from 13.33% year-on-year, indicating a slight increase in investment in innovation[3]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,961, indicating a stable shareholder base[7]. - The weighted average return on equity decreased by 0.41 percentage points to 1.96% from 2.37% in the previous year[3].

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the fiscal year, representing a 25% year-over-year growth[18]. - The company achieved operating revenue of CNY 315.46 million in 2024, representing a year-on-year growth of 28.65%[26]. - Net profit attributable to shareholders reached CNY 85.16 million, a 62.25% increase compared to the previous year[27]. - Basic earnings per share increased by 62.29% to CNY 0.2324, while diluted earnings per share also rose by the same percentage[25]. - The company reported a net cash inflow from operating activities of CNY 66.01 million, up 52.22% year-on-year[27]. - The company's total assets at the end of 2024 were CNY 1.18 billion, reflecting a 7.29% increase from the previous year[26]. - The gross margin improved to 45%, up from 40% in the previous year, due to cost optimization strategies[18]. - The net profit attributable to the parent company was 85.16 million yuan, a year-on-year increase of 62.25%, with a net profit margin significantly improved due to operational leverage[37]. Research and Development - The company is investing in R&D, allocating 10% of its revenue towards developing advanced separation technologies[16]. - Research and development expenses accounted for 13.59% of operating revenue, a decrease of 4.44 percentage points from the previous year[25]. - The R&D team has over 20 years of experience, developing advanced techniques in key areas such as microsphere synthesis and functional biomolecule synthesis, which are crucial for maintaining a competitive edge against international rivals[82]. - The company has introduced 34 new patent applications in 2024, including 28 invention patents, and has a total of 75 effective authorized patents, of which 24 are invention patents[52]. - The company has developed unique core technologies in chromatography medium preparation, which are critical for maintaining its competitive edge in the market[182]. Market Expansion and Strategy - Market expansion plans include entering the Southeast Asian market, targeting a 10% market share within the next two years[18]. - The company is exploring potential acquisitions to enhance its product portfolio, with a focus on companies specializing in biopharmaceuticals[18]. - The company has established partnerships with three major pharmaceutical firms to co-develop new therapeutic solutions[18]. - The company is actively promoting the replacement of imported materials with domestic alternatives[200]. - The company has established strategic partnerships with leading pharmaceutical companies such as Roche, Eli Lilly, and Pfizer, enhancing its innovation capabilities in drug discovery and scientific research[178]. Production and Operational Efficiency - The company maintained a 100% production plan achievement rate and order delivery rate at its Yangzhou factory during the reporting period[43]. - The Yangzhou production base commenced operations in 2021, with an annual capacity of 24,760 liters and a single batch capacity of 500 liters, making it one of the few companies in the domestic chromatography medium industry with large-scale production capabilities[63]. - The company plans to expand its production capacity to a total of 224,760 liters per year after the completion of the second phase of the Yangzhou project, further enhancing its production capabilities[179]. - The company has a large-scale production base in Yangzhou covering 41,405 square meters, with a biopharmaceutical chromatography medium capacity of 24,760 liters, ensuring stable supply for downstream drug production[179]. Risk Management - There are no significant risks that materially affect the company's operations during the reporting period[3]. - The company has disclosed potential risks in the management discussion and analysis section of the report[3]. - The company is facing risks related to potential talent loss in its high-level technical team, which is essential for ongoing innovation and development[184]. - The company faces a potential asset impairment loss of up to 8.71 million yuan and 12.15 million yuan in 2025 and 2026, respectively, if it fails to secure additional orders[190]. - The company is exposed to risks from policy changes in the pharmaceutical industry, which could slow down demand for its chromatography products[193]. Product Development and Innovation - New product launches included a novel chromatography medium that is expected to enhance purification efficiency by 15%[16]. - The company has developed a new seed swelling polymerization technology that simplifies the production process, increases efficiency, and reduces solvent and additive usage, leading to lower production costs compared to traditional methods[141]. - The company has created a core-shell chromatography medium that combines multiple separation mechanisms, breaking the long-standing market monopoly[174]. - The company has developed multiple downstream purification platform technologies across various segments, including antibodies and recombinant proteins, enabling faster adaptation for new project processes[157]. - The company has developed a unique rSPA protein sequence for affinity chromatography media, enhancing alkaline resistance and dynamic capacity[175]. Customer and Market Engagement - The company employs a direct sales model complemented by distribution for domestic sales, utilizing industry exhibitions, customer visits, and internet marketing to secure orders and maintain long-term partnerships with major pharmaceutical companies[64]. - The company has established a comprehensive sales management system, including strict regulations on contract signing, settlement methods, credit policies, and return policies[67]. - The company’s overseas business revenue accounted for 23.02% of total revenue, highlighting its global market presence[185]. - The accounts receivable balance at the end of the reporting period was 96.90 million yuan, representing 30.72% of total revenue, with a collection rate of 57.13% as of March 31, 2025[189]. Industry Trends and Market Outlook - The chromatography medium market in China is projected to reach 13.6 billion CNY in 2024, with an expected growth to 20.3 billion CNY by 2026, reflecting a compound annual growth rate (CAGR) of 22.17% from 2024 to 2026[101]. - The global chromatography medium market is expected to reach 7.5 billion USD in 2024 and grow to 9 billion USD by 2026, with a CAGR of 9.54%[102]. - The demand for chromatography products is increasing due to the rising clinical needs and the rapid development of innovative biopharmaceuticals[118]. - The domestic biopharmaceutical industry is enhancing its R&D capabilities, leading to higher demands for purification processes and creating new business opportunities for chromatography media[134]. - The global biopharmaceutical market grew from $220.2 billion in 2016 to $297.9 billion in 2020, with a CAGR of 7.85%[112].

证券代码：688758 证券简称：赛分科技 公告编号：2025-015 苏州赛分科技股份有限公司 关于取消公司监事会及修订《公司章程》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 苏州赛分科技股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召 开第二届董事会 2025 年第三次会议和第二届监事会 2025 年第二次会议，审议 通过《关于取消公司监事会及修订<公司章程>的议案》,本议案尚需提交公司 2024 年年度股东大会审议。现将相关情况公告如下： 一、关于取消公司监事会的情况 根据《中华人民共和国公司法（2023 年修订）》《上市公司章程指引（2025 年修订）》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等法律法规和规范性文件的最新规定，结合公司实际情况，现取消公司监事会， 监事会的职权由董事会审计委员会行使，《监事会议事规则》等监事会相关制度 相应废止。 二、关于修改《公司章程》的情况 鉴于上述情况，结合相关法律法规的要求，公司拟对《苏州赛分科技股份 有限公司章程》 ...

证券代码：688758 证券简称：赛分科技 公告编号：2025-017 苏州赛分科技股份有限公司 关于使用募集资金置换已支付发行费用的自筹资金 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 苏州赛分科技股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开 第二届董事会 2025 年第三次会议和第二届监事会 2025 年第二次会议，审议通过 了《关于使用募集资金置换已支付发行费用的自筹资金的议案》，同意使用募集 资金人民币 24,622,264.15 元置换已支付发行费用的自筹资金。前述事项符合募 集资金到账后六个月内进行置换的规定。公司监事会发表了明确同意的意见，中 信证券股份有限公司（以下简称"保荐人"）对本事项出具了明确的核查意见。 现将相关事项公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会核发的《关于同意苏州赛分科技股份有限公司 首次公开发行股票注册的批复》（证监许可〔2024〕1204 号），并经上海证券 交易所同意，公司首次公开发行人民币普通股（A 股）4,997.569 ...

证券代码：688758 证券简称：赛分科技 公告编号：2025-018 苏州赛分科技股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 拟聘任的会计师事务所名称：容诚会计师事务所（特殊普通合伙） 苏州赛分科技股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召 开第二届董事会 2025 年第三次会议，审议通过《关于公司续聘 2025 年度财务 和内部控制审计机构的议案》，拟续聘容诚会计师事务所（特殊普通合伙）（以 下简称"容诚"）为本公司 2025 年度的财务与内部控制审计机构，本议案尚需 提交股东大会审议。现将具体情况公告如下： 一、拟聘任会计师事务所的基本情况 截至 2024 年 12 月 31 日，容诚会计师事务所共有合伙人 212 人，共有注册 会计师 1552 人，其中 781 人签署过证券服务业务审计报告。 3.业务规模 容诚会计师事务所经审计的 2023 年度收入总额为 287,224.60 万元，其中 审计业务收入 274,873.42 ...

公司代码：688758 公司简称：赛分科技 苏州赛分科技股份有限公司 2024年度内部控制评价报告 苏州赛分科技股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能导 ...

苏州赛分科技股份有限公司 2024 年度会计师事务所履职情况评估报告 苏州赛分科技股份有限公司（以下简称"公司"）聘请容诚会计师事务所（特 殊普通合伙）（以下简称"容诚"）作为公司 2024 年度审计机构。根据财政部、 国务院国有资产监督管理委员会、中国证券监督管理委员会颁布的《国有企业、 上市公司选聘会计师事务所管理办法》，公司对容诚 2024 年度审计过程中的履职 情况进行了评估。具体情况如下： 一、会计师事务所的情况 料制品业、有色金属冶炼和压延加工业、建筑装饰和其他建筑业）及信息传输、 软件和信息技术服务业，水利、环境和公共设施管理业，科学研究和技术服务业， 批发和零售业等多个行业。对公司所在的相同行业上市公司审计客户家数为 282 家。 （三）执业记录 容诚会计师事务所近三年（最近三个完整自然年度及当年）因执业行为受到 刑事处罚 0 次、行政处罚 0 次、监督管理措施 14 次、自律监管措施 6 次、纪律 处分 2 次、自律处分 1 次。 63 名从业人员近三年（最近三个完整自然年度及当年）因执业行为受到刑 事处罚 0 次、行政处罚 3 次（同一个项目）、监督管理措施 21 次、自律监管措施 5 次 ...

董事会 根据《上市公司独立董事管理办法》《上市公司治理准则》《上海证券交易所 科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号— —规范运作》等相关法律法规及《公司章程》等公司管理制度有关规定，苏州赛 分科技股份有限公司（以下简称"公司"）董事会就公司在任独立董事彭淑贞女 士、梁永伟先生、徐锋先生的独立性情况进行评估并出具如下专项意见： 经核查独立董事彭淑贞女士、梁永伟先生、徐锋先生的任职经历及已经签署 的相关自查文件，确认上述人员未在公司担任除独立董事以外的任何职务，也未 在公司主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或 其他可能妨碍其进行独立客观判断的关系，因此，公司董事会认为，公司独立董 事符合《上市公司独立董事管理办法》《上海证券交易所科创板上市公司自律监 管指引第 1 号——规范运作》中对独立董事独立性的相关要求。 苏州赛分科技股份有限公司 苏州赛分科技股份有限公司 2024 年度董事会对独立董事独立性自查情况的专项报告 2025 年 4 月 28 日 1 ...